Viridian is currently investigating a portfolio of potentially transformative anti-insulin-like growth factor-1 receptor (IGF-1R) and anti-thyroid-stimulating hormone receptor (TSHR) monoclonal antibodies for the potential treatment of thyroid eye disease (TED). IGF-1R, is a transmembrane receptor that plays a role in development, metabolism, and immune regulation, and is a clinically and commercially validated target for the treatment of TED. Based on work in the field, IGF-1R and the co-located TSHR have been found to play a key role in the pathogenesis of TED. Viridian is making meaningful progress advancing potentially improved anti-IGF-1R and anti-TSHR antibodies for people affected by TED and expects its intravenous (IV) and subcutaneous (SC) programs to be transformative treatment options for patients.

	Veligrotug (VRDN-001) IV	Elegrobart (VRDN-003) SC	Anti-TSHR SC
Administration	Intravenous Infusion	Self-administered Subcutaneous Injection	Self-administered Subcutaneous Injection
Mechanism	Full Antagonist	Full Antagonist	Undisclosed
Phase of Development	BLA submitted	Phase 3	Preclinical
Treatment Regimen	5 infusions, given three weeks apart with 30 minute infusion time	Dosing every eight or four weeks	Undetermined
Potential Indication	TED	TED	TED & Graves' Disease

TED Program Details

Viridian’s lead product candidate, veligrotug (VRDN-001), is a potential best-in-class, IV monoclonal antibody targeting IGF-1R. Veligrotug (VRDN-001) acts as a full antagonist of IGF-1R, and based on clinical data to date, has demonstrated robust clinical activity and was generally well-tolerated.

The company conducted two positive global Phase 3 trials, THRIVE (NCT05176639) and THRIVE-2 (NCT06021054), for people living with active and chronic TED, respectively. A Biologics License Application (BLA) for veligrotug was accepted by the U.S. FDA in December 2025 and is currently under Priority Review.

Veligrotug (VRDN-001) IV Viridian’s lead product candidate, VRDN-001, is a potential best-in-class, IV monoclonal antibody targeting IGF-1R. VRDN-001 acts as a full antagonist of IGF-1R, and based on clinical data to date, has demonstrated robust clinical activity and was generally well-tolerated at Week 6 compared with the currently approved anti-IGF-1R antibody.

Viridian’s lead product candidate, VRDN-001, is a potential best-in-class, IV monoclonal antibody targeting IGF-1R. VRDN-001 acts as a full antagonist of IGF-1R, and based on clinical data to date, has demonstrated robust clinical activity and was generally well-tolerated at Week 6 compared with the currently approved anti-IGF-1R antibody.

Elegrobart is a subcutaneously delivered, half‑life‑extended monoclonal antibody targeting the insulin‑like growth factor‑1 receptor (IGF‑1R). Elegrobart has the same binding domain as veligrotug and was engineered to have a longer half-life. Elegrobart is designed to be a low volume, infrequently dosed subcutaneous IGF-1R for TED, which we believe has the potential to preserve the efficacy of anti-IGF-1Rs in TED, improve safety, and maximize convenience for patients with subcutaneous delivery.

We reported positive topline results for elegrobart from two pivotal phase 3 clinical trials, REVEAL-1 and REVEAL-2, for people living with active and chronic TED, respectively.

Viridian’s preclinical TSHR inhibitor program includes a potential best-in-class, half-life extended, monoclonal antibody that inhibits TSHR, designed for subcutaneous delivery in an autoinjector with the potential to support extended dosing intervals designed for patient convenience.

Elegrobart (VRDN-003) SC

VRDN-003 is a potential best-in-class subcutaneous monoclonal antibody targeting IGF-1R. VRDN-003 has the same binding domain as its parent molecule, VRDN-001, and was engineered to have a longer half-life. VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience and potentially improving safety. Viridian is on track to initiate two phase 3 clinical trials of VRDN-003 in August 2024.

Learn More About All Viridian Clinical Trials

View

TED Program Quote

Previous Next

It is a walk that only those that have experienced TED know the extensive damage it can cause. This goes beyond our eyes… it goes much more deeper… it affects our self-esteem. We can't even recognize ourselves… it is like our identity has been reinvented.
Person living with TED (diagnosed in 2021)
When I was diagnosed with thyroid eye disease, there were very few patient centered resources out there, and there were also a very few treatment options. And we have to do something to progress the community forward.
Person living with TED (diagnosed in 2019)
A [treatment] would mean no more TED symptoms, normal looking eyes and eyesight and a normal shaped face. A [treatment] would be stable eyes and eyesight. Living a full life instead of a life hidden or in the dark.
Person living with TED (diagnosed in 2020)

Thyroid Eye Disease
Programs

Advancing Differentiated
Anti-IGF-1R and Anti-TSHR
Antibodies in Thyroid Eye Disease

TED Program Details

TED Program Quote

Community
Corner